Clinical Trial Search

Primary: Percentage of Participants With Time to First GH Recurrence — 43; 71 Percentage of participants — p=<0.001

Primary: Number of Participants With Bacterial Vaginosis Recurrence — 8 Participants

Primary: Time to Healing of Genital Lesions — 5.1; 6.0 Days

Primary: Efficacy Will be Evaluated by the Proportion of Subjects With Non Herpes Manifestation — 73; 52 subjects

Primary: Serious Adverse Device Effects — 0 Percentage SADE's

Primary: Investigator Assessed Time to Healing of All Non-aborted Genital Herpes Lesions — 5.38; 4.79 Days — p=0.4161

Primary: Percent Change in Overall Viral Shedding Rate From Baseline (Week -7 to 0) to Post-treatment Period (Weeks 6 to 13) — 13.53 percentage change

Primary: Efficacy of 4 Different Doses of AIC316 and Matching Placebo With Respect to the Suppression of Herpes Simplex Virus Replication (Shedding Rate) — 21.2; 9.2; 2.0; 5.2…

Primary: Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2 — 35; 35 Subjects

Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants

Primary: Sensitivity of Detection of HSV DNA by GeneXpert PCR From Specimens Obtained From the Genital Tract of Non-pregnant Women in STI Clinics, as Compared With HSV Culture…

Primary: HSV Shedding Rate in Those Receiving Oral TDF, Vaginal TFV, or Double Placebo — 22.9; 13.8; 21.3; 19.5 percentage of swabs positive (%) — p=0.086

Primary: Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1) — 6; 55 Participants — p=<0.001

Primary: Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study. — 0.248; 0.294; 0.09 proportion of participants

Primary: Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study — 0.191; 0.272; 0.103 participants

Primary: Investigator-assessed Time to Healing of All Non-aborted Genital Herpes Lesions — 4.25; 4.08 days

Primary: Number of Participants With Preterm Delivery — 100; 83; 247; 5407 Participants

Primary: Percentage of Participants With a Modified sPGA-G Response at Week 16 — 19.5; 39.6 Percentage of participants — p=0.0003

Primary: Number of Participants With Solicited Local and Systemic ARs — 74; 75; 75; 74 Participants

Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants

Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)

Primary: Percentage of Participants With Healing by Day 8 — 194 Participants

Primary: Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With High-dose Acyclovir as…

Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05

Primary: The Quantity of HIV-1 RNA in Plasma While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir. — 4.08; 3.68 log10 copies/mL — p=<0.001

Primary: Effect of HSV-2 Suppression on HCV Viral Load. — .18; .03 log(IU/mL)

Primary: Herpes Simplex Virus Type 2 Recurrence — 0; 0 Recurrence

Primary: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit. — 11; 1; 9; 0 Participants — p=0.0048

Primary: Number of Subjects With Serious Adverse Events (SAEs) — 71; 42; 37 Participants

Primary: Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With High-dose Valacyclovir…